AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar
While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer, and AstraZeneca is hoping to change
A study by UK researchers has found that buying patterns for over-the-counter (OTC) medicines for pain and indigestion, recorded using a store loyalty card, could be used to pick up early s
Following the European Society of Gynaecological Oncology (ESGO) 2022 congress, pharmaphorum spoke with experts from among the Ovarian Cancer Commitment (OCC) founding partners – ESGO, the
GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patient
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio